[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368060-105":59,"doc-detail-368060-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cross-dataset-pan-cancer-detection-by-correlating-cell-free-dna-fragment-coverage-with-open-chromatin-sites-across-cell-types","Cross-dataset pan-cancer detection by correlating cell-free DNA fragment coverage with open chromatin sites across cell types","","Cross-dataset pan-cancer detection is challenged by systematic biases that limit generalization across cohorts. The study presents LIONHEART, an open-source tumor-agnostic method that correlates bias-corrected cell-free DNA (cfDNA) fragment coverage with accessible chromatin regions across 898 cell and tissue type features. The correlations infer cancer-driven shifts in cfDNA cell-type composition. Evaluation on nine datasets and fourteen cancer types yields ROC AUC 0.62–0.95 (mean 0.83), with external validation reaching 0.917.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cross-dataset-pan-cancer-detection-by-correlating-cell-free-dna-fragment-coverage-with-open-chromatin-sites-across-cell-types/368060/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cross-dataset-pan-cancer-detection-by-correlating-cell-free-dna-fragment-coverage-with-open-chromatin-sites-across-cell-types/368060.png","ImageObject",300,407,{"name":92,"@type":93},"LangkahRina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does LIONHEART address in pan-cancer detection?","Question",{"text":112,"@type":113},"Systematic biases in cfDNA fragmentation patterns hinder cross-cohort generalization. LIONHEART is designed to generalize across datasets by correlating bias-corrected fragment coverage with chromatin accessibility.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does LIONHEART use open chromatin sites?",{"text":117,"@type":113},"It correlates bias-corrected cfDNA fragment coverage across the genome with locations of accessible chromatin regions derived from 898 cell and tissue type features to infer cancer-related changes.",{"name":119,"@type":110,"acceptedAnswer":120},"What performance did LIONHEART achieve in validation?",{"text":121,"@type":113},"Across nine datasets and fourteen cancer types, it distinguishes cancer from non-cancer with ROC AUC scores from 0.62 to 0.95 (mean 0.83). External validation achieved ROC AUC 0.917.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368060,1790387741,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962090893776,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article [https://doi.org/10.1038/s41467-025-66503-3](https://doi.org/10.1038/s41467-025-66503-3)  \nCross-dataset pan-cancer detection by correlating cell-free DNA fragment coverage with open chromatin sites across cell types  \nReceived: 26 November 2024  \n\n| Accepted: 3 November 2025 |\n| --- |\n| |\n| Check for updates |\n\nLudvig Renbo Olsen 1,2, Denis Odinokov 3, Jakob Qvortrup Holsting1,2, Karoline Kondrup 1,2, Laura Iisager 1,2, Maria Rusan1,2,4, Simon Buus5,  \nBritt Elmedal Laursen1,5,6, Michael Borre 7, Mads Ryø Jochumsen 2,8,9, Kirsten Bouchelouche2,8, Amanda Frydendahl 1,2, Mads Heilskov Rasmussen1,2, Tenna Vesterman Henriksen 1,2, Marijana Nesic1,2, Christina Demuth 1,2, Sia Viborg Lindskrog 1,2, Iver Nordentoft 1,2, Philippe Lamy 1,2,  \nChristina Therkildsen 10, Lars Dyrskjøt 1,2, Karina Dalsgaard Sørensen 1,2, Claus Lindbjerg Andersen 1,2, Anders Jakobsen Skanderup 3 &  \nSøren Besenbacher 1,2,11   \nThe fragmentation patterns of whole genome sequenced cell-free DNA are promising features for tumor-agnostic cancer detection. However, systematic biases challenge their cross-cohort generalization. We introduce LIONHEART, an open source cancer detection method speciﬁcally optimized to generalize across datasets. The method correlates bias-corrected cfDNA fragment coverage across the genome with the locations of accessible chromatin regions from 898 cell and tissue type features. We use these correlations to detect changes in the cell-free DNA cell type composition caused by cancer. We test LIONHEART on nine datasets and fourteen cancer types (1106 non-cancer controls, 1449 cancers) obtained from different studies and show that it can distinguish cancer samples from non-cancer controls across cohorts with ROC AUC scores ranging from 0.62-0.95 (mean = 0.83, std = 0.12). We further validate the method on an external dataset, achieving a ROCAUC of 0.917.  \nSequencing of plasma cell-free DNA (cfDNA) offers a cost-effective and non-invasive strategy for early cancer detection. A method to detect low amounts of circulating tumor DNA (ctDNA) with high speciﬁcity and without prior knowledge of the tumor’s molecular characteristics could radically improve cancer screening. Fragmentomics, which  \nanalyzes the sequence, size, and genomic position of cfDNA fragments, is one promising approach for such tumor-agnostic detection of ctDNA1.  \nThe fragmentation patterns of cfDNA differ systematically by the cell type and release mechanism, enabling us to infer changes in the  \n1Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. 2Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. 3Genome Institute of Singapore(GIS), Agency for Science, Technology and Research(A*STAR), Singapore, Singapore. 4Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark. 5Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. 6Department of Biomedicine, Aarhus University, Aarhus, Denmark. 7Department of Urology, Aarhus University Hospital, Aarhus, Denmark. 8Department of Nuclear Medicine & PET-Centre, Aarhus University Hospital, Aarhus, Denmark. 9Department of Nuclear Medicine, Gødstrup Hospital, Herning, Denmark. 10Department of Surgical Gastroenterology, Copenhagen University Hospital-Amager Hvidovre, Hvidovre, Denmark. 11Bioinformatics Research Center, Aarhus University, Aarhus, Denmark.  \ne-mail: [besenbacher@clin.au.dk](besenbacher@clin.au.dk)  \ncontributions of different cell types to the cfDNA. Studies estimating the tissue of origin of cfDNA in healthy individuals agree that most fragments originate from hematopoietic cells with minor contributions from vascular endothelial cells and hepatocytes, although thereis no consensus on the exact proportions of these components2,3. Many common solid tumor types shed noticeable amounts of tumor DNA to the circulation1,4, making ctDNA a promising biomarker for cancer detection. The mechanisms by which DNA fragments enter the bloodstream","cbCaiqxV70UsvgqG","https://ap.wps.com/l/cbCaiqxV70UsvgqG","pdf",35499623,12,"English","# Overview\n# LIONHEART Method\n## Bias correction and fragment coverage correlations\n## Linking correlations to cell-type composition changes\n# Validation and Results\n## Testing across multiple datasets and cancer types\n## External dataset validation","[{\"question\":\"What problem does LIONHEART address in pan-cancer detection?\",\"answer\":\"Systematic biases in cfDNA fragmentation patterns hinder cross-cohort generalization. LIONHEART is designed to generalize across datasets by correlating bias-corrected fragment coverage with chromatin accessibility.\"},{\"question\":\"How does LIONHEART use open chromatin sites?\",\"answer\":\"It correlates bias-corrected cfDNA fragment coverage across the genome with locations of accessible chromatin regions derived from 898 cell and tissue type features to infer cancer-related changes.\"},{\"question\":\"What performance did LIONHEART achieve in validation?\",\"answer\":\"Across nine datasets and fourteen cancer types, it distinguishes cancer from non-cancer with ROC AUC scores from 0.62 to 0.95 (mean 0.83). External validation achieved ROC AUC 0.917.\"}]","Cross-dataset pan-cancer detection by correlating cell-free DNA fragment coverage with open chromatin sites across cell types | PDF",1790174772,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4d84dafd012eb182c7817cc2e5839b5.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00c8906f8ebefdbb2375238239690f8a.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41c64fd08e5a03c83d0ac7277638589f.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5ac8448b29104e1a340efab72c316ee.webp",980,1301]